LyondellBasell Posts Narrower Loss In Q4

LyondellBasell reported a Q4 net loss of $140 million ($0.45/share) versus a prior-year loss of $603 million ($1.87/share); adjusted loss per share was $0.26 compared with an adjusted profit of $0.77 a year earlier, and sales fell to $7.09 billion from $7.81 billion. Management highlighted $800 million of cash improvements in 2025, raised the cumulative cash-improvement target to $1.3 billion by end-2026, and announced $1.2 billion of planned 2026 capex while continuing construction of MoReTec-1; shares were up about 3.2% pre-market to $51.58. These results combine ongoing operational pressures and lower sales with meaningful cost/cash actions that could support near-term liquidity and execution risk for investors.

Analysis

Market structure: LYB’s results point to a soft end-market (sales down ~9% YoY) and margin stress, so end-users (packaging, consumer goods) temporarily gain pricing leverage while high-cost producers are squeezed. LYB’s $800m 2025 cash improvement and $1.3bn target by end-2026 shift the competitive battlefield from revenue growth to cash conversion; companies that cannot cut $/ton will lose share or be acquired. Expect near-term inventory destocking in polyolefins and polymer spreads to remain depressed until industrial PMI stabilizes (watch PMI >50 for demand recovery).

Risk assessment: Tail risks include a major plant outage or MoReTec-1 cost overrun (>$300m) that would reverse cash gains, and faster-than-expected feedstock inflation (Brent >$90/bbl or US ethane spread widening +$50/ton) that compresses margins. Immediately (days) expect stock volatility around earnings commentary; over months (1–6) cash-plan execution is binary; over years (by end-2026) realization of the $1.3bn target and MoReTec ramp determine credit profile. Hidden dependency: free cash flow hinges on successful working capital release and no incremental share buybacks or M&A drain.

Trade implications: Tactical long: bias to LYB (ticker LYB) sized 1.5–3% of equity sleeve, layered over 2–4 weeks to average in; hedge with a 6-month 45-put or 15% stop. Relative-value: pair long LYB / short DOW (ticker DOW) 1–1 base where LYB’s announced cost program should outperform peers over 6–9 months. Options: consider a 6-month 55/65 call spread (sell-side funded) sized 0.5% notional to capture upside while limiting premium; avoid uncovered longs until 1Q26 cadence is confirmed.

Contrarian angles: The market underweights cash-improvement optionality — the incremental $500m vs 2025 actuals is ~+$1.50/sh in annualized FCF at current share count if maintained, implying upside not yet priced. Reaction is mixed, not extreme; a disciplined execution could re-rate LYB by 20–30% if commodity spreads normalize modestly and MoReTec-1 delivers throughput. Conversely, capex increase to $1.2bn raises the chance of execution slippage; a contrarian short only works if feedstock volatility returns or cash targets are missed within 90 days.

Key Decisions for Investors

• Establish a 2% long position in LYB (ticker LYB) over the next 2–4 weeks, target 12-month price $65 (≈+26%), set a hard stop-loss at 15% ($≈43.85) or hedge with 6-month 45-strike puts sized to cover 75% of the position.
• Implement a relative-value pair: long LYB 1.5% vs short DOW 1.5% (equal dollar) aiming for 6–9 month horizon; unwind if spread narrows by 75% or LYB misses its Q1 2026 cash execution metrics (announce by mid-April 2026).
• Buy a limited-risk options spread: purchase a 6-month LYB 55/65 call vertical (debit) sized to 0.5% portfolio notional to capture re-rating while capping downside premium, close if LYB >$70 or implied vol spikes >+50% vs entry.
• Rotate 2% of cyclical chemical exposure (e.g., XLB weight) into specialty/defensive chemical equities such as Sherwin-Williams (SHW) to reduce exposure to commodity spread shocks; reassess after Q2 2026 PMI prints.
• Monitor three objective triggers within 30–90 days before increasing risk: (1) Q1 2026 cash-improvement update (must confirm >50% of incremental 2026 plan achieved), (2) Brent remaining < $80/bbl for 60 consecutive days, (3) no MoReTec-1 cost overrun announcements >$100m; act to add/full-size if all met.